Articles tagged "Induction therapy"

2019 American Transplant Congress
Evaluation of Rabbit Antithymocyte Globulin (rATG) Dosing and Incidence of Opportunistic Viral Infections in Kidney Transplant Recipients Using Tacrolimus (TAC), Mycophenolate (MPA) and Steroid Free Maintenance Immunosuppression
L. Von Stein, A. Leino, R. Amer, T. Pesavento, H. Winters
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: There is limited literature evaluating rATG dosing and incidence of infection with TAC/MPA and early steroid withdrawal. This study evaluates rATG dosing and overall…
2019 American Transplant Congress
Evolution of HHV6- and CMV-Specific T Cell Functional Responses and Immune Cell Populations after Kidney Transplant
A. Gil¹, M. Co², M. Calvo-Calle¹, J. Cruz¹, L. Stern¹, L. Gibson²
¹Pathology, University of Massachusetts Medical School, Worcester, MA, ²Medicine, University of Massachusetts Medical School, Worcester, MA
*Purpose: Human herpesvirus (HHV)-6 reactivation after solid organ or hematopoietic stem cell transplant has been associated with complications such as graft rejection and all-cause mortality.…
2019 American Transplant Congress
Induction Type Does Not Influence Kidney Graft or Patient Survival in Recipients with a Previous Lung Transplant in the United States
S. Riad¹, U. Goswami², S. Jackson³, M. Hertz²
¹Medicine, University of Minnesota, Eden Prairie, MN, ²Medicine, University of Minnesota, Minneapolis, MN, ³Complex Care Analytics, Fairview Health Services, Minneapolis, MN
*Purpose: Induction regimens for kidney transplant alone (KT) in lung recipients vary widely among transplant centers. We sought to examine the impact of kidney induction…
2019 American Transplant Congress
Effect of Induction Therapy on Absolute CD4 Count and CD4 Percentage in HIV Positive Kidney Transplant Recipients
S. A. Kuten¹, I. E. Dunne¹, A. E. Cantwell¹, M. J. Hobeika², S. G. Yi², W. Musick¹, R. J. Knight², A. O. Gaber²
¹Pharmacy, Houston Methodist Hospital, Houston, TX, ²Surgery, Houston Methodist Hospital, Houston, TX
*Purpose: Anti-thymocyte globulin (ATG) induction causes profound and long-lasting lymphocyte depletion, with CD4+ reconstitution lagging behind other subsets. While absolute CD4 count is the preferred…
2019 American Transplant Congress
A Randomized Controlled Clinical Trial of Thymoglobulin® and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection after Liver Transplantation: A Multicenter Study
L. Coromina¹, S. Shah², B. Xervos³, M. Zimmerman⁴, K. Sasaki¹, T. Diago¹, K. Hashimoto¹, F. Aucejo¹, m. Fujiki¹, H. Block-Beach¹, A. Patterson², C. Miller¹, C. Quintini¹, B. Eghtesad¹
¹The Cleveland Clinic, Cleveland, OH, ²University of Cincinnati, Cincinnati, OH, ³The Cleveland Clinic, Weston, FL, ⁴Medical College of Wisconsin, Milwaukee, WI
*Purpose: Thymoglobulin® (r-ATG) has been used as induction therapy in liver transplantation (LT). No prospective, randomized, controlled, trial (RCT) has been performed to evaluate effect…
2019 American Transplant Congress
Alemtuzumab versus Anti-Thymocyte Globulin Induction in the Setting of Immediate Post-Renal Transplant Acute Tubular Necrosis in an Urban, Minority Patient Population
K. Tejani, E. Benedetti, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: Post-renal transplant (RTx) delayed graft function (DGF) or slow graft function (SGF) increase the risk of rejection and impair allograft function. Lymphocyte depleting induction…
2019 American Transplant Congress
Incidence of Viral Infections in Kidney Transplant Recipients with Alemtuzumab or Rabbit Antithymocyte Globulin Induction
A. Brueckner¹, C. Truong¹, E. Yanqui¹, R. Baliga², L. Bowman¹
¹Tampa General Hospital, Tampa, FL, ²Florida Kidney Physicians, Tampa, FL
*Purpose: Monoclonal antibody therapy causes profound and sustained lymphocyte depletion thus increasing the risk of viral infections. While studies exist evaluating the outcomes of alemtuzumab…
2019 American Transplant Congress
Effect of Induction Therapy on Outcomes of De Novo Renal Transplant Recipients Receiving Everolimus with Reduced-Dose Calcineurin Inhibitor: 24-Month Results from the TRANSFORM Study
R. Oberbauer¹, F. Vincenti¹, O. Viklicky¹, U. Huynh-Do¹, D. Kim¹, J. M. Cruzado¹, Y. Qazi¹, M. S. Kim¹, P. Narvekar², M. P. Hernandez Gutierrez², P. Bernhardt², D. Kuypers¹
¹TRANSFORM Study Group, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
*Purpose: To assess the effect of induction therapy on efficacy and safety outcomes of de novo renal transplant recipients (RTxR) receiving everolimus with reduced calcineurin…
2019 American Transplant Congress
Living Donor Renal Transplantation without Any Induction Immunosuppression in Spousal Donors – Single Center Experience
R. Bhat, F. Aziz, I. N. Abubecker, S. Narayanan, B. Hafeeque
Nephrology & Transplantation, Malabar Instiute of Medical Sciences, Calicut, India
*Purpose: Renal transplantation in India is primarily driven by living related donation; parents and spouse constitute 70% of donors in India. Some centres use induction…
2019 American Transplant Congress
A Prospective, Randomized, Multicenter Trial of Bela-Based CNI Free and Steroid Withdrawal Immunosuppression: Best Trial Two Year Characterization of Rejection and Renal Function
A. Wiseman¹, A. R. Shields², R. R. Alloway², D. Kaufman³, J. P. Leone⁴, A. J. Matas⁵, P. West-Thielke⁶, J. Lipscomb², E. King², E. S. Woodle for the BEST Study Group²
¹University of Colorado School of Medicine, Denver, CO, ²University of Cincinnati, Cincinnati, OH, ³University of Wisconsin, Madison, WI, ⁴Tampa General, Tampa, FL, ⁵University of Minnesota, Minneapolis, MN, ⁶University of Illinois, Chicago, Chicago, IL
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal Trial) was designed to compare two BELA-based early steroid withdrawal (ESW) regimens with a TAC-based ESW regimen…